Skip to main content
. 2023 Jan 18;4(3):e140–e148. doi: 10.1016/S2666-5247(22)00337-8

Figure 3.

Figure 3

SARS-CoV-2 RBD-specific antibodies

Vertical lines indicate the first and second ABNCoV2 vaccination (28 days after first vaccination). (A) Concentration of RBD-specific antibodies of groups 1 to 3 (6 μg, 12 μg, and 25 μg ABNCoV2; non-adjuvanted [groups labelled A] and MF59-adjuvanted [groups labelled B]) up to day 42 after the first vaccination (14 days after the second vaccination). (B) Concentration of RBD-specific antibodies of groups 1A, 2A, 3A, 4, and 5 (6 μg, 12 μg, 25 μg, 50 μg, and 70 μg) 14 days after second vaccination. (C) Concentration of RBD-specific antibodies of groups receiving the optimal doses 25 μg and 50 μg ABNCoV2 until day 42 after the first vaccination. (D) Concentration of RBD-specific antibodies of groups receiving the optimal doses 25 μg and 50 μg ABNCoV2 until day 196 after the first vaccination (end-of-study visit). Different colours indicate types of licensed SARS-CoV-2 vaccines that participants received during the follow-up period. RBD=receptor binding domain.